SCHEMBL9997304

SCHEMBL9997304

COc1cc(F)ccc1-c1cccc(S(=O)(=O)Nc2ccc(C(=O)O)c(O)c2)c1

nearest known ligand 0.75

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PFKFB3 Q16875 5/20 0.75
MCL1 Q07820 1/20 0.49
LMNA P02545 2/20 0.47
ACLY P53396 1/20 0.46
KDM4E B2RXH2 2/20 0.45
FABP4 P15090 1/20 0.45
FABP5 Q01469 1/20 0.45
ALDH1A1 P00352 2/20 0.44
HSD17B10 Q99714 1/20 0.44
KMT2A Q03164 2/20 0.44
MAP2K4 P45985 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
NR3C1 P04150 1/20 0.44
PLAU P00749 1/20 0.43
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9996992 0.92 PFKFB3 (0.78) PFKFB3MCL1LMNAACLYKDM4E
SCHEMBL9997250 0.90 PFKFB3 (0.68) PFKFB3MCL1LMNAACLYALDH1A1
SCHEMBL9997473 0.89 PFKFB3 (0.70) PFKFB3MCL1LMNAKDM4EFABP4
SCHEMBL9997154 0.87 PFKFB3 (0.82) PFKFB3MCL1LMNAKDM4EFABP4
SCHEMBL9997201 0.86 PFKFB3 (0.66) PFKFB3MCL1LMNAACLYFABP4
SCHEMBL15056118 0.86 PFKFB3 (1.00) PFKFB3MCL1ALDH1A1HSD17B10KMT2A
SCHEMBL9997264 0.85 PFKFB3 (0.86) PFKFB3MCL1FABP4FABP5ALDH1A1
SCHEMBL9997958 0.84 PFKFB3 (0.63) PFKFB3MCL1ACLYFABP4ALDH1A1
SCHEMBL9997026 0.83 PFKFB3 (0.62) PFKFB3MCL1ACLYALDH1A1HSD17B10
SCHEMBL9997220 0.83 PFKFB3 (0.80) PFKFB3MCL1ALDH1A1HSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 WO claimed
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 US disclosed
WO-2020080979-A1 PFKFB3 INHIBITORS AND THEIR USES GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) 2020-04-23 WO disclosed
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 WO disclosed
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES PFKFB3, PFKFB4, PFKFB1 PFKFB3 1/4885MCL1 1411/4885LMNA 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.